{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:03:34Z","timestamp":1794384214608,"version":"4.9.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jpsychires.2023.07.005","type":"journal-article","created":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T14:35:37Z","timestamp":1689518137000},"page":"77-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Short communication: Prevalence of long-acting injectable antipsychotic use in Canadian early intervention services for psychosis"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4933-180X","authenticated-orcid":false,"given":"Kyle A.","family":"McKee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice E.","family":"Crocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Dikaios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Otter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bardell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Andr\u00e9","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Abdel-Baki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Palaniyappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Tibbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2023.07.005_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/YIC.0000000000000310","article-title":"Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis","volume":"35","author":"Abdel-Baki","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib2","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1517\/14656566.2010.499125","article-title":"Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention","volume":"11","author":"Agid","year":"2010","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The barnes akathisia rating scale\u2013revisited","volume":"17","author":"Barnes","year":"2003","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib4","doi-asserted-by":"crossref","first-page":"s37","DOI":"10.1192\/bjp.195.52.s37","article-title":"Antipsychotic long-acting injections: prescribing practice in the UK","volume":"195","author":"Barnes","year":"2009","journal-title":"Br. J. Psychiatr. Suppl."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib5","first-page":"1","article-title":"Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: a mirror-image study","author":"Bartoli","year":"2022","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114405","article-title":"Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: findings from the STAR Network Depot Study","volume":"309","author":"Bartoli","year":"2022","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/j.eurpsy.2020.72","article-title":"Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: a retrospective 6-month mirror-image study","volume":"63","author":"Bioque","year":"2020","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/acps.13411","article-title":"Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: a state sequence analysis approach","volume":"145","author":"Brodeur","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/acps.13413","article-title":"Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: a Real\u2010World Observational Study","volume":"145","author":"Brodeur","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the extrapyramidal symptom rating scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.psychres.2018.09.041","article-title":"One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia","volume":"270","author":"Fefeu","year":"2018","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib12","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","article-title":"The Clinical Global Impression\u2013Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib14","unstructured":"Hastings, T. (n.d.). Tool for monitoring antipsychotic side effects (TMAS) [WWW Document]. URL 10.31.22 https:\/\/www.epicanada.org\/tmas."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib15","first-page":"14","article-title":"A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I\u2014patient perspectives","volume":"58","author":"Iyer","year":"2013","journal-title":"Crim. Justice Pol. Rev."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib16","first-page":"23","article-title":"A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part II\u2014physician perspectives","volume":"58","author":"Iyer","year":"2013","journal-title":"Crim. Justice Pol. Rev."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/j.1440-1614.2000.00728.x","article-title":"Psychotic disorders in urban areas: an overview of the study on low prevalence disorders","volume":"34","author":"Jablensky","year":"2000","journal-title":"Aust Nz J Psychiat"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia","volume":"77","author":"Kane","year":"2020","journal-title":"Jama Psychiat"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpsychires.2020.10.009","article-title":"Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: a meta-analysis of randomized trials for schizophrenia","volume":"132","author":"Kishi","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre\u2013post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/eip.13202","article-title":"Efficacy of long\u2010acting injectable versus oral antipsychotic drugs in early psychosis: a systematic review and meta\u2010analysis","volume":"16","author":"Lian","year":"2022","journal-title":"Early Interv Psychia"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","article-title":"Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis","volume":"35","author":"Lin","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40261-020-00900-y","article-title":"Hospitalization rates and therapy costs of German schizophrenia patients who are initiated on long-acting injectable medication: a mirror-image study","volume":"40","author":"Mahlich","year":"2020","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib24","first-page":"30","article-title":"Long-acting injectable antipsychotics: recommendations for clinicians","volume":"58","author":"Malla","year":"2013","journal-title":"CanJPsychiatry"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib25","first-page":"5","article-title":"Long-acting injectable antipsychotics: evidence of effectiveness and use","volume":"58","author":"Manchanda","year":"2013","journal-title":"Crim. Justice Pol. Rev."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1186\/s12888-021-03646-9","article-title":"Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study","volume":"21","author":"McKee","year":"2021","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0000000000001082","article-title":"Long-acting injectables versus oral antipsychotics: a retrospective bidirectional mirror-image study","volume":"39","author":"Miura","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1440-1614.2003.01110.x","article-title":"Use of antipsychotic medications in Australia between july 1995 and december 2001","volume":"37","author":"Mond","year":"2003","journal-title":"Aust. N. Z. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/0706743716632516","article-title":"Early intervention for psychosis in Canada","volume":"61","author":"Nolin","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/0004867419837358","article-title":"Long-acting atypical antipsychotics in schizophrenia: a systematic review and meta-analyses of effects on functional outcome","volume":"53","author":"Olagunju","year":"2019","journal-title":"Aust. N. Z. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","article-title":"Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis","volume":"178","author":"Ostuzzi","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41537-023-00342-3","article-title":"Clinical trajectories of individuals with severe mental illness continuing and discontinuing long-acting antipsychotics: a one-year mirror-image analysis from the STAR Network Depot study","volume":"9","author":"Ostuzzi","year":"2023","journal-title":"Schizophrenia"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320924789","article-title":"Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study","volume":"10","author":"Pappa","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40263-016-0350-7","article-title":"Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia","volume":"30","author":"Parellada","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib35","first-page":"361","article-title":"Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-analysis","volume":"16","author":"Park","year":"2018","journal-title":"Clin Psychopharm Neu"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0920-9964(01)00312-7","article-title":"Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder","volume":"57","author":"Robinson","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib37","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0706743720901975","article-title":"The evolution of long-acting antipsychotics use in Qu\u00e9bec between 2003 and 2017","volume":"65","author":"Roy","year":"2020","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/070674371105600608","article-title":"Les antipsychotiques injectables \u00e0 action prolong\u00e9e: avis d\u2019experts de l'Association des m\u00e9decins psychiatres du Qu\u00e9bec","volume":"56","author":"Stip","year":"2011","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib39","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/0706743719847193","article-title":"Antipsychotiques \u00e0 Action Prolong\u00e9e: R\u00e9vision de l\u2019algorithme QAAPAPLE","volume":"64","author":"Stip","year":"2019","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","article-title":"Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia","volume":"197","author":"Taipale","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218071","article-title":"Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary","volume":"14","author":"Tak\u00e1cs","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jpsychires.2023.07.005_bib42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jpsychires.2020.06.013","article-title":"Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: a systematic review and meta-analysis","volume":"129","author":"Uribe","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2016.09.014","article-title":"Antipsychotic long-acting injections: a community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation","volume":"178","author":"Verdoux","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib44","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/088740341305805s01","article-title":"Why are Canadians complacent about long-acting injectable antipsychotic therapies? Come on, Canada, you can do better","volume":"58","author":"Weiden","year":"2013","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0447.2006.00757.x","article-title":"Medication decisions and clinical outcomes in the Canadian national outcomes measurement study in schizophrenia","volume":"113","author":"Williams","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.schres.2016.02.037","article-title":"Comparison of treatment effectiveness and medical costs for different long-acting injectable antipsychotics in patients with schizophrenia in Taiwan: a nationwide population-based cohort study","volume":"173","author":"Wu","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2023.07.005_bib47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5414\/CPP46245","article-title":"Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China","volume":"46","author":"Xiang","year":"2008","journal-title":"Int. J. Clin. Pharm. Ther."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395623003448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395623003448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:42:57Z","timestamp":1763048577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395623003448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":47,"alternative-id":["S0022395623003448"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2023.07.005","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short communication: Prevalence of long-acting injectable antipsychotic use in Canadian early intervention services for psychosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2023.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}